Waterhouse RL, et al. - Experts assessed an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men who underwent repeat biopsy. They also compared the accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. An epigenetic assay to assess the need for repeat biopsy was successfully validated in this group of AA men. Consistent results with previous studies from predominantly Caucasian populations were noted. Hence, for risk stratification of AA men who had an initial negative biopsy, the ConfirmMDx assay was a useful tool.